Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 80

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 80
---
 could be adversely affected by changes in national or global economic conditions. These conditions include but are not limited
to inflation, rising interest rates, availability of capital markets, energy availability and costs, the negative impacts caused
by pandemics and public health crises, negative impacts resulting from the military conflict between Russia and the Ukraine, and the effects
of governmental initiatives to manage economic conditions. Impacts of such conditions could be passed on to our business in the form of
higher costs for labor and materials, higher investigator fees, possible reductions in pharmaceutical industry-wide spending on research
and development and acquisitions and higher costs of capital.

Public health threats could have an
adverse effect on our operations and financial results.

Public health threats, such
as the novel coronavirus (COVID-19), influenza and other highly communicable diseases or viruses could adversely impact our operations
and disrupt our ongoing or planned research and development activities. We cannot presently predict the scope and severity of any potential
future business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including the suppliers, clinical
trial sites, regulators and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions,
our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted.

We are exposed to risks related to currency
exchange rates.

We conduct a significant portion
of our operations outside of the United States. Because our financial statements are presented in U.S. dollars, changes in currency exchange
rates have had and could have in the future a significant effect on our operating results when our operating results are translated into
U.S. dollars.

Our employees,
principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance
with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.

We are exposed to the risk
of fraud or other misconduct by our employees, principal investigators, consultants and collaborators, including intentional failures
to comply with FDA or Office of Inspector General regulations or similar regulations of comparable non-U.S. regulatory authorities, provide
accurate information to the FDA or comparable non-U.S. regulatory authorities, comply with manufacturing standards we have established,
comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced
by comparable non-U.S. regulatory authorities, report financial information or data accurately or disclose unauthorized activities to
us. Misconduct by these parties could